Drug Development
Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.
FEATURED STORIES
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging field.
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment.
As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: speeding drug development.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
The report also highlighted that an unvaccinated individual is five times more likely to get COVID-19 than someone who is fully vaccinated.
Shares of Tonix Pharmaceuticals were up nearly 11% in premarket trading after the company announced plans to initiate a Phase II study of TNX-102 SL as a potential treatment for Long COVID Syndrome following a positive meeting with the U.S. FDA.
President Biden is expected to be briefed on the lab leak theory conducted over the last 90 days. Very few expect solid results, although this might provide direction for more lines of inquiry.
Izencitinib was generally well tolerated and its safety data were consistent with expectations, but it failed to achieve its primary endpoint. Here’s more about it.
The new authorization is expected to be the final reassurance for many of those who had hesitated when the vaccine was approved under emergency use only.
Novartis reported that its Kymriah failed to hit its primary endpoint in the Phase III BELINDA trial in aggressive B-cell non-Hodgkin lymphoma after relapse or lack of response to first-line treatment.
An oral version of remdesivir is being developed by scientists at the University of California San Diego to combat the SARS-CoV-2 virus early in its infection cycle.
While last flu season saw fears of a “twindemic” go largely unfounded, there are fears that recent lockdowns could also lead to a lack of natural immunity against the flu.
Research presented earlier this month discussed a possible link between COVID-19 and long-term cognitive deficits and how it may accelerate the pathology and symptoms of Alzheimer’s disease.
Many expect the full approval will lead to vaccine mandates, as that was one of the obstacles to it for many organizations.